Myosin IXb, a member of the myosin superfamily, is a molecular motor that possesses a GTPase activating protein (GAP) for Rho. Through the yeast two-hybrid screening using the tail domain of myosin IXb as bait we found BIG1, a guanine nucleotide exchange factor for ADP-ribosylation factor ( 
It is well established that Rho GTPases act as molecular switches that cycle between the GTP-bound on state and the GDP-bound off state and play key roles in diverse cellular functions under the control of two major regulators: a GTPase activating protein (GAP) 1 that enhances the hydrolysis of GTP and thus makes Rho GTPases in GDP-bound forms, and a guanine nucleotide exchange factor (GEF) that promotes the exchange of GDP to GTP and thereby turns them on to the GTP-bound form (1) . The numbers of the regulators for the Rho family GTPases found in mammals are reported to be ϳ80 for GAPs and about 60 for GEFs (2) . Even though the numbers may be lowered because they are likely to contain some redundant counts (3), the numbers exceed far more than the number of Rho GTPases (i.e. 20, Ref. 2) , which leads us to think that Rho GTPases must be tightly regulated in a spatial and temporal manner. Such regulations will seem to be more crucial when we see how diverse functions are controlled by Rho GTPases: migration, adhesion, morphogenesis, axon guidance, and phagocytosis, as in the actin-dependent processes, and the microtubule cytoskeleton, cell polarity, gene expression, cell cycle progression, and membrane transport pathways, examples of other functions besides actin-related functions (4) .
As a member of the ninth class of the myosin superfamily, which now consists of 18 classes (5), myosin IX has a motor domain that is common throughout the superfamily, and IQ domains that serve as the light chain binding sites. One of the unique features of myosin IX is that it possesses a RhoGAP domain and a zinc finger motif in the tail domain (6) . Two isoforms are known in myosin IX: myosin IXa and IXb (7, 8) . Although they have a zinc finger motif and a GAP domain in common, they differ in the number of the light chain binding IQ motif, where IXa-isoform has six and IXb has four, and the length of the tail domain, where the tail of IXa is ϳ70 kDa longer than that of IXb (8) . It is also reported that the two isoforms differ in their expression patterns in human tissues; IXa are mainly expressed in brain and testis, whereas IXb are found more ubiquitously (7) . However, the physiological function of IXb is largely unknown. It was shown recently that myosin IXb is a processive motor (9, 10) that moves on the actin track for a long distance without dissociating from actin. This finding suggests that myosin IX functions as a cargo carrier in cells. A critical issue is the identity of such cargo molecules for myosin IX.
To address this question, we attempted to find a binding partner of myosin IXb by using yeast two-hybrid screening strategy. As a result, we obtained BIG1, a GEF for another member of the Ras GTPase superfamily Arf. Among all six members of Arfs, Arf1 and -3, which are known to play a role in several types of vesicle formation on the Golgi (11), were preferentially activated by BIG1 (12, 13) . In the present study, we demonstrated that BIG1 as a new binding partner of myosin IXb down-regulates the GAP activity of myosin IXb through the competition in RhoA binding.
Francisco, CA) against the C-terminal peptides: CSASTESLLEERAVR-GAAEE and CSQPPEQELGINKQ for anti-myosin IXb and anti-BIG1 antibodies, respectively. Antibodies used in this study are all affinity purified with the antigen peptides and stored at Ϫ80°C.
Yeast Two-hybrid Assays-The LexA system was used in the yeast two-hybrid assays. As for bait to be used in the yeast two-hybrid screening, myr5 (GenBank TM accession number X77609), the rat homolog of myosin IXb, was digested at BamHI and SalI sites that were created by the site-directed mutagenesis in the position of 4229 and 6090 nucleotides, respectively. This tail portion of myr5 was then inserted in-frame and ligated into pBTM-116 at BamHI/SalI sites. The rat lung Matchmaker cDNA library was purchased from Clontech. Both bait and the library vectors were used for co-transformation of yeast L40 strain, which has LacZ and HIS3 reporter genes. The transformants streaked on a plate lacking Trp/Leu and incubated at 30°C. Colonies grown on the plate were replicated on a ϪHis plate and selected for potential positive clones. After colonies were restreaked on a His plate, the plate was replicated on four plates, each lacking either ϪTrp, ϪLeu, ϪHis or none, to confirm the positive clones grown on a ϪHis plate without the loss of bait or prey vector. The positive colonies were further tested for the ␤-galactosidase (␤-gal) assay by first transferring them onto a blotting paper, freezing and thawing the colonies once with liquid nitrogen, and incubating them with buffer containing 100 mM NaHPO 4 , 10 mM KCl, 1 mM MgSO 4 and 0.5 mg/ml 5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside at 30°C for 2 h. For the yeast two-hybrid binding assay, five constructs were made using the tail portion of myr5, and the residues included are: pBTM-P (amino acids 1364 -1593), pBTM-PZ (amino acids 1364 -1657), pBTM-ZG (amino acids 1532-1855), pBTM-GA (amino acids 1659 -1980), and pBTM-A (amino acids 1836 -1980). All of these constructs were co-transformed with the rat BIG1 cDNA (4023-5961 nucleotides) in pACT2, which was isolated in the screening, and tested for its interactions in the same way as described above.
Molecular Cloning of Human BIG1 and Plasmid Constructions for Protein Expression-Human full-length BIG1 was cloned by reverse transcription-PCR. The template cDNA was generated from the HeLa cell total RNA using Superscript reverse transcryptase II (Invitrogen) with specific oligonucleotide primers according to the manufacturer's protocol. The BIG1 cDNA was inserted in-frame to FLAG-tagged pFastBacHT at BamHI/SalI sites. Human myosin IXb cDNA encoding the entire coding region (GenBank TM accession number NM_004145.2, the short version with exon 36 spliced out) was inserted in-frame to FLAGtagged pFastBacHT at EcoRI/SpeI sites. The tail portion of this myosin IXb (M9b-tail, amino acids 1252-2005) was subcloned in-frame to pFastBacHT using the SpeI site. RhoA cDNA containing the entire coding sequence was subcloned in-frame to pFastBacHT using the EcoRI site.
Protein Purification-All proteins were produced by the baculovirus expression system according to the manufacturer's protocol. For Histagged protein purification, Sf9 cells infected with recombinant baculovirus were harvested and centrifuged, and the pellets were suspended in a buffer containing 30 mM Tris-HCl, pH 7.5 at 4°C, 150 mM NaCl, 1 mM EGTA, 10 g/ml leupeptin, and 25 g/ml trypsin inhibitor. After sonication, the cell suspension was centrifuged at 20,000 ϫ g for 20 min. The supernatant was incubated with Ni-NTA-agarose and gently rotated for 20 min at 4°C. After a wash with the buffer described above, the bound protein was eluted with a buffer containing 150 mM imidaz- and pulled down with anti-FLAG M2 affinity gel. After the wash, the immunoprecipitated samples were subjected to the SDS-PAGE analysis. B, the binding of M9b-tail to BIG1 as a function of the concentration of M9b-tail. The pull-down assay was performed using a fixed amount of FLAG-tagged BIG1 (0.5 M) incubated with the indicated concentrations of M9b-tail. Precipitated protein samples were subjected to SDS-PAGE analysis, and the amount of protein on the gel was determined by densitometry. Bars represent the standard error of three independent experiments. ole, pH 7.5, 150 mM NaCl, and 10 g/ml leupeptin. The purified protein was dialyzed against phosphate-buffered saline containing 0.2 mM EGTA and 0.2 mM DTT; then sucrose was added to 20%, and the protein was snap-frozen in liquid nitrogen and stored at Ϫ80°C. For FLAGtagged proteins, the infected Sf9 cells were lysed in the same buffer described above, except that 2 mM ATP was added for the myosin IXb purification, the cells were centrifuged at 300,000 ϫ g for 20 min, and the supernatant was passed through the column containing anti-FLAG M2 affinity gel. After an extensive wash with the lysis buffer, the recombinant proteins were eluted with a buffer containing 30 mM Tris-HCl, pH 7.5, at 4°C, 150 mM NaCl, 1 mM EGTA, 5 g/ml leupeptin, and 0.1 mM FLAG peptide. The purified proteins were then stored at Ϫ80°C as described above. M9b-tail, RhoA, and Arf1 are flanked by His tag, and full-length myosin IXb and BIG1 were flanked by His-FLAG tag. These are used in the experiments unless otherwise indicated. After the initial purification step by Ni-NTA-agarose, myristoylated Arf1 was separated as described (14) . Briefly, Arf1 purified by Ni-NTAagarose was applied to the phenyl-Sepharose HP column, and the protein was eluted with a descending NaCl gradient from 3000 to 100 mM in 20 mM Tris-HCl, pH 8.0, 1 mM MgCl 2 , and 1 mM DTT. Arf1-containing fractions were collected, concentrated, and dialyzed against the same buffer with 100 mM NaCl. The purified Arf1 was stored at Ϫ80°C as described above.
Protein Binding Assay-In vitro pull-down assay was performed using anti-FLAG M2 affinity gel. The FLAG-tagged protein was first bound to the beads in the solution containing phosphate-buffered saline and 10 mg/ml BSA. After a brief wash with the same buffer, the beads were incubated with the full-length or the tail portion of myosin IXb for 30 min at 4°C in the binding buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 5 mM MgCl 2 , and 10% glycerol). Beads were spun down and washed twice with 70 times the bed volume of the binding buffer. Then the bound proteins were subjected to SDS-PAGE. The kinetic parameters for the protein binding activity were determined by the non-linear regression analysis using GraphPad Prism software. For the binding assay of RhoA on M9b-tail, Ni-NTA-agarose was used. His-tagged M9b-tail and RhoA were incubated with the beads in the binding buffer as described above. RhoA was treated with TEV protease (Invitrogen) to remove the tag according to the manufacturer's protocol before incubating with the beads. The binding reaction was carried out in the binding buffer for 30 min at 4°C, and the beads were washed twice with 70 times the bed volume of the binding buffer. Then the bound proteins were subjected to SDS-PAGE followed by Western blot. Endogenous BIG1 or myosin IXb of NRK cells were co-immunoprecipitated with or without the purified FLAG-tagged proteins (0.5 M) using the anti-FLAG M2 antibody. The NRK lysate was prepared by homogenizing the cell pellets with 9-fold volumes of the lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EGTA, 2 mM ATP, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, 2 g/ml pepstatin A, 0.1 mM L-1-tosylamido-2-phenylethyl chloromethyl ketone, 0.1 mM 1-chloro-3-tosylamido-7-amino-2-heptanone, 1 g/ml trypsin inhibitor, and 0.1% Triton X-100), incubating the cell pellets on ice for 20 min, washing them three times with the lysis buffer, and centrifuging them at 18,000 ϫ g for 10 min thus obtaining the supernatants. The supernatants were subjected to SDS-PAGE followed by the Western blot analysis using antibodies as indicated in the figures. The co-immunoprecipitation assay for the endogenous protein complex was carried out in the same way as described above except that the extract was made by adding the lysis buffer of four times the volume of the cell pellets. 0.2 mg/ml final of either the affinity purified anti-BIG1 antibody or non-immune IgG was added to the lysate and incubated for 3 h at 4°C. The complex was centrifuged, and the pellets were subjected to the Western blot analysis.
GAP Assay-To measure the GTPase activity of RhoA, the filter binding assay was performed based on the protocol described previously (15) with some modifications. First, 5 M RhoA was preloaded with [␥-32 P]GTP in the preloading buffer (15 M [␥-32 P]GTP, 20 mM HEPES, pH 7.5, 50 mM NaCl, 1 mM EDTA, and 0.1 mM DTT) for 10 min at 30°C. The preloading was stopped by adding MgCl 2 to 5 mM. For the measurement of the intrinsic GTPase activity of RhoA, 1 M RhoA was incubated at 30°C for 10 min in the solution containing 20 mM HEPES, pH 7.5, 50 mM NaCl, 5 mM MgCl 2 , 0.1 mM DTT, 0.1 mM GTP, and 1 mg/ml BSA. A part of the sample was taken at each time point into 1 ml of dilution buffer (20 mM Tris-HCl, pH 8.0, at 4°C, 50 mM NaCl, and 5 mM MgCl 2 ), which was immediately filtered through 25-mm BA85 FIG. 3. Immunoprecipitation of myosin IXb and BIG1 in NRK cells. NRK cells were lysed and either FLAG-tagged myosin IXb (0.5 M) (A) or FLAG-tagged BIG1 (0.5 M) (B) was added to the extract with anti-FLAG M2 affinity gel. After they were centrifuged, the beads were washed and then subjected to SDS-PAGE followed by the Western blot analysis using anti-BIG1 antibody or anti-myosin IXb antibody. C, endogenous myosin IXb was immunoprecipitated with endogenous BIG1 using anti-BIG1 antibodies or non-immune IgG and detected by Western blot. BIG1 pulled down with anti-BIG1 antibody or non-immune IgG is shown on the lower panel.
FIG. 4. The BIG1 binding region in the myosin IXb tail domain.
Five constructs containing various regions of M9b-tail were subjected to the yeast two-hybrid assay. The constructs were made using the pBTM vector, and each of them contained one or two of the four distinct regions in M9b-tail: a proline-rich region, a zinc finger motif, a GAP domain, and a region enriched in acidic amino acid residues. The rat BIG1 cDNA (4023-5961 nucleotides) in pACT2 was used as a binding counterpart. The yeast co-transformants were grown on ϪTrp/ϪLeu plates followed by replicating onto ϪHis plates. The colonies grown on ϪHis plates were subjected to ␤-gal assay.
nitrocellulose membranes (Schleicher & Schuell) washed with 5 ml of the dilution buffer. The radioactivity of the membrane filter was determined by the scintillation counter. For the measurement of the GAP activity of myosin IXb, the tail domain or full-length myosin IXb was added to the reaction mixture containing 1 M [␥-
32 P]GTP-bound RhoA with or without BIG1 at indicated concentrations. IC 50 for the inhibition of the GAP activity of myosin IXb by BIG1 was determined by the non-linear regression analysis using GraphPad Prism software. The GAP activity of myosin IXb for Arf1 was measured as described above except that 2.4 mg/ml of asolectin (Sigma, catalog number 11145), which was sonicated in the preloading buffer for 20 s, was added to Arf1 for GTP preloading.
GEF Assay-To measure the exchange of GTP/GDP on Arf1, the filter binding assay was carried out based on the protocol described previously (13) Fig. 9 . 50 l of the reaction mixture was diluted into 1 ml of dilution buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, and 5 mM MgCl 2 ), which was immediately filtered through the nitrocellulose membranes. The membrane was washed with 5 ml of the dilution buffer, and the radioactivity was measured by the scintillation counter.
RESULTS
To find a new binding partner for myosin IXb, we performed the yeast two-hybrid screening. Because the N-terminal domain serves a motor function, it has been thought that the C-terminal tail domain serves as a targeting protein binding site. Using the C-terminal region that includes the zinc finger motif and the GAP domain as bait (Fig. 1) , approximately three million independent clones were screened from the rat lung cDNA library. The positive clones grown on the nutrient selection plates were picked and were subjected to ␤-gal assay to further eliminate false positives using LacZ, a GAL4-responsive gene encoding ␤-galactosidase. Five clones that encoded the C-terminal domain of BIG1 (amino acids 1305-1849) were obtained as positive clones. To confirm the interaction of BIG1 with bait, an additional yeast two-hybrid assay was performed in which the DNA binding domain and the gene activation domain were switched for BIG1 and the myosin IXb tail domain. The positive signal was observed, suggesting the interaction of the myosin IXb tail domain and the C-terminal portion of BIG1 in this assay system.
The binding of BIG1 to myosin IXb was directly examined with the purified proteins. Based on the predicted nucleotide sequence of BIG1 from the human genome, the entire region of human BIG1 was cloned by reverse transcription-PCR using cDNA raised from the total RNA of HeLa cells. The FLAG sequence was introduced at the N-terminal end of BIG1 in aid of purification. FLAG-tagged BIG1 was expressed in Sf9 insect cells and purified using anti-FLAG affinity chromatography. The SDS-PAGE analysis of the purified BIG1 showed an apparent molecular mass of ϳ210 kDa, which is consistent with the calculated molecular mass of BIG1 (Fig. 2) . The tail domain of human myosin IXb (M9b-tail) flanked by a hexahistidine tag at the N-terminal end of the molecule was also expressed in Sf9 and purified by using Ni-NTA-agarose affinity chromatography. To examine the direct binding between the two proteins, the purified proteins were mixed and then applied to anti-FLAG affinity gel. The resin was washed and subjected to SDS-PAGE to analyze the bound proteins. As shown in Fig. 2A , His-tagged M9b-tail was bound together with FLAG-tagged BIG1. On the other hand, the binding of M9b-tail to the resin was not observed in the absence of FLAG-tagged BIG1, suggesting that there was no nonspecific binding of M9b-tail to the resin. The result indicates that BIG1 directly binds to myosin IXb. The amount of bound M9b-tail was determined as a function of the BIG1 concentration. The amount of BIG1-bound M9b-tail increased with the increasing concentration of M9b-tail that was added in the sample solution. The amount of BIG1-bound M9b-tail was plotted against the concentration of M9b-tail incubated with BIG1 (Fig. 2B) . The non-linear curve fitting gave the calculated value of B max ϭ 0.93 mol/mol and K d ϭ 0.37 M, indicating that myosin IXb and BIG1 bind with P]GTP was incubated with or without M9b-tail, and the remaining radioactivity was measured after 10 min of incubation at 30°C. The assay conditions are as described under "Experimental Procedures." 100% refers to the amount of [␥-32 P]GTP bound to RhoA in the absence of M9b-tail after the incubation. Bars represent the standard error of three independent experiments. B, the inhibition of the RhoGAP activity by BIG1 as a function of the BIG1 concentration. The GAP activity was determined as the ratio of decrement in the RhoA-bound radioactivity of [␥-32 P]GTP caused by the intrinsic GTPase activity of RhoA. The GAP activity of 100% was set as the value in the absence of BIG1. The addition of BIG1 significantly inhibited the GAP activity with the calculated IC 50 of 0.06 M. C, inhibition of the GAP activity of full-length myosin IXb by BIG1. The assay was performed as described above except that the full-length of myosin IXb was used instead of M9b-tail. the stoichiometry of 1 to 1 at the submicromolar binding affinity.
To examine the binding that takes place between wild type myosin IXb and BIG1, full-length myosin IXb was added to the total cell extract of NRK cells, and the mixture was immunoprecipitated with anti-FLAG antibodies. As shown in Fig. 3A , endogenous BIG1 was co-immunoprecipitated with FLAGtagged full-length myosin IXb. There was no BIG1 detected in the precipitate when myosin IXb was not added to the extract, suggesting that the binding was specific. Likewise, endogenous myosin IXb in the cell extract was co-immunoprecipitated with FLAG-tagged BIG1 (Fig. 3B) . The results suggest that BIG1 and myosin IXb bind to each other in vivo. The binding between endogenous myosin IXb and BIG1 was also demonstrated by co-immunoprecipitation using the anti-BIG1 antibody in the NRK extract (Fig. 3C) . The results further support the idea that the binding of myosin IXb and BIG1 actually takes place in physiological conditions. It should be noted that the amount of myosin IXb co-immunoprecipitated with BIG1 was lower for the endogenous protein than that for the recombinant myosin IXb (Fig. 3B ), but this should be caused by the difference in the myosin IXb concentration in the assay solution that affects the binding efficiency according to the K d value of 0.37 M.
It is known that the myosin IX tail is composed of several domains including the RhoGAP domain and the zinc finger motif (6) . In the tail domain, myosin IXb has a proline-rich region at the N-terminal end, a zinc finger to follow, then a RhoGAP domain, and the C-terminal acidic residue-rich region (Fig. 4) . By the yeast two-hybrid assay, we determined the domain in myosin IXb responsible for the BIG1 binding. Five different constructs of the truncated M9b-tail were produced and tested for the BIG1 binding activity. One construct with both the zinc finger motif and the GAP domain yielded positive signal for both ϪHis growth and ␤-gal assay (Fig. 4) . On the other hand, the constructs containing only the GAP domain or the zinc finger region were negative in these assays. The result suggests that both the RhoGAP domain and the zinc finger motif of myosin IXb are needed for the binding to BIG1.
As the BIG1 binding region overlaps with RhoA interacting domain, we examined whether BIG1 shows any functional effects on myosin IXb. The GAP activity of myosin IXb was measured by using a filter binding assay, and the effect of the BIG1 on the GAP activity of myosin IXb was determined. RhoA was preloaded with [␥-32 P]GTP followed by incubation with or without M9b-tail and then filtered through the nitrocellulose membrane. The amount of [␥-
32 P]GTP remaining on RhoA showed a dramatic decrease with the addition of the increasing amount of M9b-tail. This was consistent with the previous reports (6, 9, 16) and showed that M9b-tail has the RhoAGAP activity. However the GAP activity of M9b-tail was significantly attenuated when 0.1 M of BIG1 was added (Fig. 5A) . A similar result was obtained using full-length myosin IXb (Fig.  5C ). The inhibition of the RhoAGAP activity of myosin IXb by BIG1 was observed in a dose-dependent manner, and the IC 50 was calculated to be 0.06 M (Fig. 5B) .
Because the BIG1 binding region contains the RhoGAP domain, we examined whether the binding of RhoA on myosin IXb is affected by the addition of BIG1. The binding assay was performed with His-tagged M9b-tail and RhoA in the presence of various concentrations of BIG1. The effect of BIG1 on the amount of RhoA bound to M9b-tail was determined by Western blot. Interestingly, the binding of RhoA to myosin IXb was diminished by the addition of BIG1 in a dose-dependent manner, whereas addition of BSA showed no change (Fig. 6) . Likewise, when FLAG-tagged BIG1 was mixed with M9b-tail in the presence of various concentrations of RhoA, the bound M9b-tail to BIG1 decreased significantly as higher concentrations of RhoA was added (Fig. 7) . These results suggest that the inhibition of the GAP activity by BIG1 is caused by BIG1 interfering with the binding of RhoA to myosin IXb.
As BIG1 is known as ArfGEF, we tested to see if myosin IXb is involved in the Arf1 signaling pathway by testing the GAP activity for Arf1. As shown in Fig. 8 , no GAP activity for Arf1 was observed at the concentrations of M9b-tail tested, i.e. up to 1 M, which was 1,000-fold the amount used for RhoGAP assay. We also tested to see if myosin IXb has an effect on the ArfGEF activity of BIG1. The GEF assay was performed to observe the effect of myosin IXb in the rate of [
35 S]GTP␥S incorporation into Arf1 in the presence or absence of BIG1. The incorporation of [
35 S]GTP␥S into Arf1 was significantly enhanced in the presence of BIG1, indicating the GEF activity of BIG1 (Fig. 9) . However, the addition of M9b-tail up to 1 M hardly changed the incorporation of down-regulator for the RhoGAP activity of myosin IXb by interfering with the binding of the myosin IXb GAP domain to RhoA.
DISCUSSION
It has been thought that the tail domain of myosin serves as myosin target protein binding sites. For myosin IX, it was previously shown that the tail domain contains a RhoGAP domain. This finding raised an idea that myosin IX is a signaling molecule having motor function. In the present study we demonstrated that BIG1, which has the GEF activity against Arf family GTPases, interacts with the tail domain of myosin IXb by using the yeast two-hybrid screening. Endogenous BIG1 and myosin IXb in cells were co-immunoprecipitated, supporting the idea that the interaction between the two proteins takes place in the cell. Furthermore, we found that the purified BIG1 binds to the purified myosin IXb tail indicating the direct binding between the two proteins. A critical finding is that the RhoGAP activity of myosin IXb is inhibited by BIG1. The IC 50 for BIG1 in the inhibition of the GAP activity was similar to the dissociation constant for the binding of the two proteins, supporting the hypothesis that the inhibition of the RhoGAP activity that is induced by BIG1 is caused by the binding of BIG1 to myosin IXb. This is consistent with the finding that the domain in myosin IXb responsible for the binding to BIG1 is the region containing the zinc finger motif and the GAP domain. Because the BIG1 binding domain includes the GAP domain of myosin IXb, it is most likely that competition between BIG1 and Rho in binding to myosin IXb takes place. The present results support this notion that the BIG1 interferes with the binding of RhoA to the GAP domain of myosin IXb thus inhibiting the RhoGAP activity.
It has become clear that the Golgi membranes associate with the actin network and the actin structure is important for the overall organization of the Golgi (17) . Furthermore, it has been suggested that the Rho family plays a role in the modification of the Golgi structure and positioning presumably because of the change in the actin network. The localization of BIG1 at the Golgi has been observed in various culture cells (12, 18) . Meanwhile, it was reported that myosin IXb is observed throughout the cytoplasm with some punctate patterns along with actin stress fibers and enrichment at the perinuclear region including the Golgi (16) . These observations together with the present findings raise an idea that the RhoGAP activity of myosin IXb is spatially regulated by the localized concentration of BIG1. Recent studies have suggested that actin filaments extend from the Golgi membrane, and Rho and its associated proteins play a role in polymerization of actin from the Golgi membrane (19) . Therefore, it is anticipated that the RhoGAP activity of myosin IXb at the Golgi is inhibited by BIG1 thus preventing the inhibition of the RhoA activity by myosin IXb at the Golgi.
It is known that there is a dynamic traffic system that delivers proper proteins and lipids to various intracellular organelles including the Golgi. The transport carriers include several coat proteins such as COPI, COPII, and clathrin, and it is thought that the Arf family of small GTPases play a major role in the recruitment of coat proteins on the Golgi (20) . The Arf activity is regulated by specific ArfGEFs. Among various ArfGEFs, BIG1 is classified in Sec7/BIG family containing the central sec7 domain catalyzing the exchange of GDP for GTP (11) . BIG1 is localized in the cytosol and the Golgi, and it is anticipated that the localization of BIG1 is determined by unknown transportation mechanisms. The present study shed a light in the transportation of sec7/BIG family ArfGEF and thus the regulation of the Arf activity at the Golgi and the recruitment of coat proteins on the Golgi. It was shown previously that the truncation mutants of BIG1 lacking the Cterminal domain can localize to the Golgi (12) . In the present study, we found that the C-terminal domain of BIG1 contains the myosin IXb binding region. Therefore, it is possible that myosin IXb moves BIG1 away from the Golgi rather than moves into the Golgi. There are some recent findings that support this notion. One study have revealed that RhoA assembles on the Golgi membrane along with other effector proteins, suggesting that actin filaments elongate from the Golgi with minus ends pointing outward (19) . Also, our recent study revealed unique motor characteristics of myosin IXb. It was shown that myosin IXb moves processively toward the minus end of the actin filament (10) . Therefore, myosin IXb is a suitable motor that carries BIG1 away from the Golgi on actin filaments for a long distance without dissociating from actin filaments. Because the RhoGAP activity of myosin IXb would be controlled by the local concentration of BIG1 and RhoA, it is anticipated that the RhoGAP activity of myosin IXb is resumed at the destination where BIG1 dissociates from myosin IXb by unknown mechanisms.
Recent studies have suggested that the cAMP/protein kinase A signaling pathway is involved in the function of BIG1. It is known that BIG1 forms a heterodimer with BIG2 (13, 21) . Recently it was reported that BIG2 harbors protein kinase A binding sites, suggesting that protein kinase A is a component of the BIG1/BIG2 complex (22) . It has been reported that BIG1 changes its localization within the cell by the stimulation of cAMP signaling; BIG1 changes its localization from the cytosol to membrane/cytoskeletal components (22) . Consistently, it was also reported that the activation of protein kinase A enhances the binding of Arf1 to the Golgi membrane (23) , and this may be caused by the accumulation of BIG1 at the Golgi membrane. At present, we do not know whether myosin IXb is involved in this regulatory process, but because recent studies have suggested the cross-talk between cAMP and Rho signaling (24) it is possible that myosin IXb, having the actin-based motor, the RhoGAP, and the BIG1 binding activities, plays a role in the Arf-related membrane trafficking process.
